View ValuationVytrus Biotech 将来の成長Future 基準チェック /06現在、 Vytrus Biotechの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Personal Products 収益成長8.4%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 02Vytrus Biotech, S.A., Annual General Meeting, Jun 02, 2026Vytrus Biotech, S.A., Annual General Meeting, Jun 02, 2026. Location: calle blasco de garay 29-49, edifici cambra de comerc, terrassa., SpainValuation Update With 7 Day Price Move • Apr 13Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €19.75, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 17x in the Personal Products industry in Europe. Total returns to shareholders of 506% over the past three years.New Risk • Apr 09New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 23% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). High level of non-cash earnings (23% accrual ratio).Valuation Update With 7 Day Price Move • Mar 26Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €15.20, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 16x in the Personal Products industry in Europe. Total returns to shareholders of 375% over the past three years.Valuation Update With 7 Day Price Move • Mar 12Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €12.80, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 16x in the Personal Products industry in Europe. Total returns to shareholders of 277% over the past three years.Valuation Update With 7 Day Price Move • Feb 17Investor sentiment improves as stock rises 25%After last week's 25% share price gain to €12.90, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 17x in the Personal Products industry in Europe. Total returns to shareholders of 286% over the past three years.分析記事 • Feb 04Investors Appear Satisfied With Vytrus Biotech, S.A.'s (BME:VYT) Prospects As Shares Rocket 32%Vytrus Biotech, S.A. ( BME:VYT ) shares have continued their recent momentum with a 32% gain in the last month alone...Valuation Update With 7 Day Price Move • Feb 03Investor sentiment improves as stock rises 19%After last week's 19% share price gain to €11.00, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 17x in the Personal Products industry in Europe. Total returns to shareholders of 228% over the past three years.分析記事 • Jan 29Here's Why Vytrus Biotech (BME:VYT) Has Caught The Eye Of InvestorsInvestors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Valuation Update With 7 Day Price Move • Dec 11Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €9.40, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 16x in the Personal Products industry in Europe. Total returns to shareholders of 185% over the past three years.Valuation Update With 7 Day Price Move • Nov 03Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €7.30, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 18x in the Personal Products industry in Europe. Total returns to shareholders of 124% over the past three years.分析記事 • Oct 29Investors Still Waiting For A Pull Back In Vytrus Biotech, S.A. (BME:VYT)With a price-to-earnings (or "P/E") ratio of 25.8x Vytrus Biotech, S.A. ( BME:VYT ) may be sending bearish signals at...New Risk • Sep 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Spanish stocks, typically moving 5.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (5.9% average weekly change). Minor Risk Market cap is less than US$100m (€45.1m market cap, or US$52.8m).Valuation Update With 7 Day Price Move • Jul 25Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €5.70, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 17x in the Personal Products industry in Europe. Total returns to shareholders of 90% over the past three years.分析記事 • Jul 22After Leaping 29% Vytrus Biotech, S.A. (BME:VYT) Shares Are Not Flying Under The RadarDespite an already strong run, Vytrus Biotech, S.A. ( BME:VYT ) shares have been powering on, with a gain of 29% in the...Buy Or Sell Opportunity • Jul 21Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 75% to €5.10. The fair value is estimated to be €4.22, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 17%.New Risk • Jul 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 5.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (5.1% average weekly change). Market cap is less than US$100m (€34.1m market cap, or US$40.1m).Valuation Update With 7 Day Price Move • Jun 06Investor sentiment improves as stock rises 21%After last week's 21% share price gain to €4.08, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 19x in the Personal Products industry in Europe. Total returns to shareholders of 17% over the past three years.お知らせ • May 29Vytrus Biotech, S.A. announced that it has received €1.2 million in funding from Boyser S.R.L and other investorsVytrus Biotech, S.A. announced a private placement of 506,329 common shares at a price of €2.37 per share for the gross proceeds of €1,200,000 on May 29, 2025. The transaction included participation from Boyser S.R.L and other investors.お知らせ • May 19Vytrus Biotech, S.A., Annual General Meeting, Jun 17, 2025Vytrus Biotech, S.A., Annual General Meeting, Jun 17, 2025. Location: calle blasco de garay 29-49, edifici cambra de comerc, terrassa., SpainBuy Or Sell Opportunity • May 15Now 21% undervaluedOver the last 90 days, the stock has risen 29% to €3.26. The fair value is estimated to be €4.12, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last year, while earnings per share has been flat.分析記事 • Apr 29Returns Are Gaining Momentum At Vytrus Biotech (BME:VYT)There are a few key trends to look for if we want to identify the next multi-bagger. Typically, we'll want to notice a...New Risk • Apr 28New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (€24.1m market cap, or US$27.4m).Reported Earnings • Oct 15First half 2024 earnings released: EPS: €0.068 (vs €0.053 in 1H 2023)First half 2024 results: EPS: €0.068 (up from €0.053 in 1H 2023). Revenue: €3.03m (up 21% from 1H 2023). Net income: €510.7k (up 42% from 1H 2023). Profit margin: 17% (up from 14% in 1H 2023). The increase in margin was driven by higher revenue.New Risk • Jul 17New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (5.0% increase in shares outstanding). Market cap is less than US$100m (€18.6m market cap, or US$20.2m).お知らせ • May 14Vytrus Biotech, S.A., Annual General Meeting, Jun 12, 2024Vytrus Biotech, S.A., Annual General Meeting, Jun 12, 2024. Location: cl blasco de garay 29-49, edifici cambra de comerc., terrassa SpainNew Risk • Mar 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (26% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (4.4% average weekly change). Market cap is less than US$100m (€13.6m market cap, or US$14.9m).Reported Earnings • Oct 26First half 2023 earnings released: EPS: €0.053 (vs €0.049 in 1H 2022)First half 2023 results: EPS: €0.053 (up from €0.049 in 1H 2022). Revenue: €2.50m (up 4.2% from 1H 2022). Net income: €358.9k (up 7.0% from 1H 2022). Profit margin: 14% (in line with 1H 2022). Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 5.3% growth forecast for the Personal Products industry in Europe.New Risk • Oct 21New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 26% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (26% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Revenue is less than US$5m (€4.6m revenue, or US$4.9m). Market cap is less than US$100m (€17.1m market cap, or US$18.1m).New Risk • Oct 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Share price has been volatile over the past 3 months (5.5% average weekly change). Revenue is less than US$5m (€4.5m revenue, or US$4.7m). Market cap is less than US$100m (€17.4m market cap, or US$18.3m).分析記事 • Sep 26Pinning Down Vytrus Biotech, S.A.'s (BME:VYT) P/E Is Difficult Right NowVytrus Biotech, S.A.'s ( BME:VYT ) price-to-earnings (or "P/E") ratio of 27.2x might make it look like a strong sell...Valuation Update With 7 Day Price Move • Sep 18Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €2.10, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 19x in the Personal Products industry in Europe. Total loss to shareholders of 35% over the past year.Reported Earnings • Mar 30Full year 2022 earnings releasedFull year 2022 results: Revenue: €4.48m (up 28% from FY 2021). Net income: €605.3k (up 35% from FY 2021). Profit margin: 14% (in line with FY 2021). Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 4.8% growth forecast for the Personal Products industry in Europe.Buying Opportunity • Mar 28Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 5.9%. The fair value is estimated to be €4.02, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 48% over the last year. Meanwhile, the company has become profitable.Buying Opportunity • Feb 27Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 4.1%. The fair value is estimated to be €4.11, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 48% over the last year. Meanwhile, the company has become profitable.Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Oct 25First half 2022 earnings releasedFirst half 2022 results: Net income: €335.3k (up €335.3k from 1H 2021). Revenue is forecast to grow 5.9% p.a. on average during the next 2 years, compared to a 5.7% growth forecast for the Personal Products industry in Europe. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Vytrus Biotech は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測BME:VYT - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202510314N/A9/30/20259213N/A12/31/20246112N/A9/30/20246102N/A6/30/20245101N/A3/31/20245101N/A12/31/20235101N/A9/30/20235101N/A6/30/202351-11N/A3/31/20235101N/A12/31/20224101N/A9/30/20224101N/A6/30/20224100N/A3/31/20224100N/A12/31/20214000N/A12/31/20202000N/A12/31/201920N/AN/AN/A12/31/201810N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: VYTの予測収益成長が 貯蓄率 ( 2.7% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: VYTの収益がSpanish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: VYTの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: VYTの収益がSpanish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: VYTの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: VYTの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHousehold 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/08 12:40終値2026/05/08 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Vytrus Biotech, S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Marisa Luisa Mazo FajardoGVC Gaesco Valores
お知らせ • May 02Vytrus Biotech, S.A., Annual General Meeting, Jun 02, 2026Vytrus Biotech, S.A., Annual General Meeting, Jun 02, 2026. Location: calle blasco de garay 29-49, edifici cambra de comerc, terrassa., Spain
Valuation Update With 7 Day Price Move • Apr 13Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €19.75, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 17x in the Personal Products industry in Europe. Total returns to shareholders of 506% over the past three years.
New Risk • Apr 09New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 23% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). High level of non-cash earnings (23% accrual ratio).
Valuation Update With 7 Day Price Move • Mar 26Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €15.20, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 16x in the Personal Products industry in Europe. Total returns to shareholders of 375% over the past three years.
Valuation Update With 7 Day Price Move • Mar 12Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €12.80, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 16x in the Personal Products industry in Europe. Total returns to shareholders of 277% over the past three years.
Valuation Update With 7 Day Price Move • Feb 17Investor sentiment improves as stock rises 25%After last week's 25% share price gain to €12.90, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 17x in the Personal Products industry in Europe. Total returns to shareholders of 286% over the past three years.
分析記事 • Feb 04Investors Appear Satisfied With Vytrus Biotech, S.A.'s (BME:VYT) Prospects As Shares Rocket 32%Vytrus Biotech, S.A. ( BME:VYT ) shares have continued their recent momentum with a 32% gain in the last month alone...
Valuation Update With 7 Day Price Move • Feb 03Investor sentiment improves as stock rises 19%After last week's 19% share price gain to €11.00, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 17x in the Personal Products industry in Europe. Total returns to shareholders of 228% over the past three years.
分析記事 • Jan 29Here's Why Vytrus Biotech (BME:VYT) Has Caught The Eye Of InvestorsInvestors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Valuation Update With 7 Day Price Move • Dec 11Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €9.40, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 16x in the Personal Products industry in Europe. Total returns to shareholders of 185% over the past three years.
Valuation Update With 7 Day Price Move • Nov 03Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €7.30, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 18x in the Personal Products industry in Europe. Total returns to shareholders of 124% over the past three years.
分析記事 • Oct 29Investors Still Waiting For A Pull Back In Vytrus Biotech, S.A. (BME:VYT)With a price-to-earnings (or "P/E") ratio of 25.8x Vytrus Biotech, S.A. ( BME:VYT ) may be sending bearish signals at...
New Risk • Sep 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Spanish stocks, typically moving 5.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (5.9% average weekly change). Minor Risk Market cap is less than US$100m (€45.1m market cap, or US$52.8m).
Valuation Update With 7 Day Price Move • Jul 25Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €5.70, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 17x in the Personal Products industry in Europe. Total returns to shareholders of 90% over the past three years.
分析記事 • Jul 22After Leaping 29% Vytrus Biotech, S.A. (BME:VYT) Shares Are Not Flying Under The RadarDespite an already strong run, Vytrus Biotech, S.A. ( BME:VYT ) shares have been powering on, with a gain of 29% in the...
Buy Or Sell Opportunity • Jul 21Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 75% to €5.10. The fair value is estimated to be €4.22, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 17%.
New Risk • Jul 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 5.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (5.1% average weekly change). Market cap is less than US$100m (€34.1m market cap, or US$40.1m).
Valuation Update With 7 Day Price Move • Jun 06Investor sentiment improves as stock rises 21%After last week's 21% share price gain to €4.08, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 19x in the Personal Products industry in Europe. Total returns to shareholders of 17% over the past three years.
お知らせ • May 29Vytrus Biotech, S.A. announced that it has received €1.2 million in funding from Boyser S.R.L and other investorsVytrus Biotech, S.A. announced a private placement of 506,329 common shares at a price of €2.37 per share for the gross proceeds of €1,200,000 on May 29, 2025. The transaction included participation from Boyser S.R.L and other investors.
お知らせ • May 19Vytrus Biotech, S.A., Annual General Meeting, Jun 17, 2025Vytrus Biotech, S.A., Annual General Meeting, Jun 17, 2025. Location: calle blasco de garay 29-49, edifici cambra de comerc, terrassa., Spain
Buy Or Sell Opportunity • May 15Now 21% undervaluedOver the last 90 days, the stock has risen 29% to €3.26. The fair value is estimated to be €4.12, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last year, while earnings per share has been flat.
分析記事 • Apr 29Returns Are Gaining Momentum At Vytrus Biotech (BME:VYT)There are a few key trends to look for if we want to identify the next multi-bagger. Typically, we'll want to notice a...
New Risk • Apr 28New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (€24.1m market cap, or US$27.4m).
Reported Earnings • Oct 15First half 2024 earnings released: EPS: €0.068 (vs €0.053 in 1H 2023)First half 2024 results: EPS: €0.068 (up from €0.053 in 1H 2023). Revenue: €3.03m (up 21% from 1H 2023). Net income: €510.7k (up 42% from 1H 2023). Profit margin: 17% (up from 14% in 1H 2023). The increase in margin was driven by higher revenue.
New Risk • Jul 17New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (5.0% increase in shares outstanding). Market cap is less than US$100m (€18.6m market cap, or US$20.2m).
お知らせ • May 14Vytrus Biotech, S.A., Annual General Meeting, Jun 12, 2024Vytrus Biotech, S.A., Annual General Meeting, Jun 12, 2024. Location: cl blasco de garay 29-49, edifici cambra de comerc., terrassa Spain
New Risk • Mar 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (26% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (4.4% average weekly change). Market cap is less than US$100m (€13.6m market cap, or US$14.9m).
Reported Earnings • Oct 26First half 2023 earnings released: EPS: €0.053 (vs €0.049 in 1H 2022)First half 2023 results: EPS: €0.053 (up from €0.049 in 1H 2022). Revenue: €2.50m (up 4.2% from 1H 2022). Net income: €358.9k (up 7.0% from 1H 2022). Profit margin: 14% (in line with 1H 2022). Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 5.3% growth forecast for the Personal Products industry in Europe.
New Risk • Oct 21New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 26% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (26% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Revenue is less than US$5m (€4.6m revenue, or US$4.9m). Market cap is less than US$100m (€17.1m market cap, or US$18.1m).
New Risk • Oct 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Share price has been volatile over the past 3 months (5.5% average weekly change). Revenue is less than US$5m (€4.5m revenue, or US$4.7m). Market cap is less than US$100m (€17.4m market cap, or US$18.3m).
分析記事 • Sep 26Pinning Down Vytrus Biotech, S.A.'s (BME:VYT) P/E Is Difficult Right NowVytrus Biotech, S.A.'s ( BME:VYT ) price-to-earnings (or "P/E") ratio of 27.2x might make it look like a strong sell...
Valuation Update With 7 Day Price Move • Sep 18Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €2.10, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 19x in the Personal Products industry in Europe. Total loss to shareholders of 35% over the past year.
Reported Earnings • Mar 30Full year 2022 earnings releasedFull year 2022 results: Revenue: €4.48m (up 28% from FY 2021). Net income: €605.3k (up 35% from FY 2021). Profit margin: 14% (in line with FY 2021). Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 4.8% growth forecast for the Personal Products industry in Europe.
Buying Opportunity • Mar 28Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 5.9%. The fair value is estimated to be €4.02, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 48% over the last year. Meanwhile, the company has become profitable.
Buying Opportunity • Feb 27Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 4.1%. The fair value is estimated to be €4.11, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 48% over the last year. Meanwhile, the company has become profitable.
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Oct 25First half 2022 earnings releasedFirst half 2022 results: Net income: €335.3k (up €335.3k from 1H 2021). Revenue is forecast to grow 5.9% p.a. on average during the next 2 years, compared to a 5.7% growth forecast for the Personal Products industry in Europe.